Lipoprotein(a) in Diabetic Patients with and Without Chronic Renal Failure
- Pierre Jean Guillausseau, MD,
- Jacqueline Peynet, PHD,
- Philippe Chanson, MD,
- Alian Legrand, PHD,
- Jean Jacques Altman, MD,
- Joel Poupon, PHD,
- Maï N'Guyen, MD,
- François Rousselet, PHD and
- Jean Lubetzki, MD
- Department of Medicine B., and the University Paris VII., Laboratory of Biochemistry, Hôpital Lariboisiere Paris, France
- Address Correspondence and reprint requests to P.J. Guillausseau, MD, Department of Medicine B., Hôpital Lariboisiere, 75475 Paris, Cedex 10, France.
Abstract
OBJECTIVE To examine the distribution of Lp(a) plasma levels in patients with IDDM and NIDDM, and in nondiabetic and IDDM patients with chronic renal failure.
RESEARCH DESIGN AND METHODS Cross-sectional study of Lp(a) plasma levels in a population of diabetic patients with stable metabolic control, with simultaneous determination of plasma lipids, fasting plasma glucose, and HbA1. Thirty-six patients with IDDM, 90 with NIDDM, and 41 with chronic renal failure (20 IDDM, 21 nondiabetic) were compared with 78 control subjects.
RESULTS Lp(a) plasma levels were significantly higher in IDDM and NIDDM patients, as well as in nondiabetic and IDDM patients with chronic renal failure compared with control subjects. No correlation was observed between Lp(a) and lipid plasma levels, fasting plasma glucose, and HbA1.
CONCLUSIONS Lp(a) may contribute to the increased prevalence of atherosclerotic disease in diabetic patients and patients with chronic renal failure, especially in IDDM patients whose lipoprotein pattern was not different from that of the control group.
- Received October 21, 1991.
- Accepted January 16, 1992.
- Copyright © 1992 by the American Diabetes Association
